BENEFIT

Children

ALLOWS REAL-TIME ACCESS CATALOG TO OVER-THE-COUNTER PRODUCTS
ALLOWS REAL-TIME PRESCRIBING CAPABILITIES
ASSESS IF INHIBITOR OR INDUCER AND SUBSTRATE OF METABOLIZING ENZYMES OR TRANSPORTERS
ASSESS IMPACT TO CHANGE IN AUC
BIOAVAILABILITY OF DRUG FROM FORMULATION
BIOEQUIVELANCE OF TEST VS REFERENCE
CAN BE READILY ACCESSIBLE TO ALL PERSONS WITH INITIAL TEST GROUP UNTIL SCALABLE
DETERMINATION IF HEMODIALYSIS COULD BE USED FOR DRUG OVERDOSAGE
DOSAGE RECOMMENDATION FOR DIFFERENT STAGES OF RENAL IMPAIRMENT
DOSAGE RECOMMENDATIONS FOR DIFFERENT STAGES OF HEPATIC IMPAIRMENT
EFFECT OF FOOD ON BIOAVAILABILITY OF ORAL DRUG
EFFECT OF HEMODIALYSIS ON DRUG DOSAGE
EFFECT OF HEPATIC IMPAIRMENT ON PHARMACOKINETICS OF PARENT COMPOUND AND METABOLITES
EFFECT OF RENAL IMPAIRMENT ON DRUG CLEARANCE
ELIMINATION (URINE PHARMACOKINETICS, METABOLITE IDENTIFICATION)
ELIMINATION AND EXCRETION PROFILE
ENABLE COMPLETE MEDICATION THERAPY MANAGEMENT
ENABLE POST-APPROVAL STUDY DATA COLLECTION
ENABLE REAL-TIME ACCESS TO COMPLETE MEDICAL RECORDS (PATIENT AND PROVIDER)
ENABLE REAL-TIME ACCESS TO HEALTH INSURANCE INFORMATION (PATIENT AND PROVIDER)
ENABLE REAL-TIME ACCESS TO LAB AND DIAGNOSTIC RESULTS FOR FAST PROVIDER ACCESS
FAST AND LOW COST WAY TO OBTAIN PRIOR AUTHORIZATION
GENERAL PHARMACOKINETICS (VARIABILITY, LINEARITY, DOSE PROPORTIONALITY)
IDENTIFY IF COMPOUND PROLONGS QT AND NEEDS MORE EKG MONITORING IN STUDIES
LABELING INSTRUCTION TO ADMINISTER WITH OR WITHOUT MEALS
MAXIMUM TOLERATED DOSE (MTD)
MORE COST-EFFECTIVE THAN TRAVEL TO PHYSICAL SPACE
PATIENT CAN BE EXTRACTED IN NEAR-REAL TIME IF WORSENS
PATIENT CAN BE PROVIDED DIAGNOSTIC AND-OR THEAPEUTIC INTERVENTION IN NEAR REAL-TIME
PATIENT CAN BE REMOTELY MONITORED WITHOUT TRAVEL OR EXTRA TIME
PATIENT CAN OBTAIN ACCESS TO MEDICAL ASSISTANCE IN NEAR-REALTIME
PATIENT HAS FAST ACCESS TO PROVIDERS WITH MINIMAL WAIT
PATIENT IS ABLE TO ACCESS WORLD-CLASS HEALTHSYSTEM FROM HOME
PRECEDENT (PROVIDING TREATMENT IN SPACE, ON A SMALL POPULATION REMOTE EARTH AREA, IN MOTION IN A VEHICLE
PRODUCTS SHOULD BE FAIRLY AFFORDABLE
PROPORTION OF PARENT COMPOUND CONVERTED TO METABOLITE
PROVIDES ASSURANCE TO FAMILIES A NEAR REAL-TIME STATUS ON HEALTH OF PATIENT FAMILY MEMBER
RATE (CMAX, TMAX) AND ABSORPTION (AUC) OF DRUG FROM TEST FORMULATION
REQUIRES MINIMAL SOFTWARE AND PHYSICAL HARDWARE WHEN POSSIBLE
SAFETY AND TOLERABILITY
SHOULD BE INSTALLABLE IN ANY ENVIRONMENT
STEADY-STATE PARAMETERS (ACCUMULATION, TIME-DEPENDENCY)
SYSTEMS NEED TO BE CLEARED BY REGULATORS FOR PAYOR TRUST

Made with TheBrain